(Q37081486)

18 August 2017

1 reference

title

Update on the natural history and systemic treatment of psoriasis (English)

1 reference

18 August 2017

Stephen K Richardson

1

1 reference

18 August 2017

Joel M Gelfand

series ordinal

2

1 reference

18 August 2017

language of work or name

1 reference

1 January 2008

1 reference

18 August 2017

Advances in dermatology

1 reference

18 August 2017

24

1 reference

18 August 2017

171-196

1 reference

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

29 September 2017

Psoriasis comorbidities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

The effect of weight on the efficacy of biologic therapy in patients with psoriasis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

The genetic basis of psoriasis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Smoking and the risk of psoriasis in women: Nurses' Health Study II.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Interleukin-12, interleukin-23, and psoriasis: current prospects

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Pathogenesis and clinical features of psoriasis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Pathogenesis and therapy of psoriasis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Psoriasis: genetic associations and immune system changes.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Lymphoma risk in psoriasis: results of the PUVA follow-up study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Relapse, rebound, and psoriasis adverse events: an advisory group report.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

The benefit/risk profile of TNF-blocking agents: findings of a consensus panel

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Clinical considerations of efalizumab therapy in patients with psoriasis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Clinical pharmacokinetics of TNF antagonists: how do they differ?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Genetic epidemiology of psoriasis and psoriatic arthritis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

The genetics of psoriasis 2001: the odyssey continues

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Dermal injection of immunocytes induces psoriasis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Adhesion receptors of the immune system

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Malignant tumours and psoriasis: climatotherapy at the Dead Sea.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Malignant tumours and psoriasis: a follow-up study

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Early onset (< 40 years age) psoriasis is comorbid with greater psychopathology than late onset psoriasis: a study of 137 patients.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Experience with psoriasis in a psychosomatic dermatology clinic.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Feelings of stigmatization in patients with psoriasis.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Psoriasis and alexithymia.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Keratinocyte growth regulation by the products of immune cells

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Increased occurrence of psoriasis in patients with Crohn's disease and their relatives

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

The risk of mortality in patients with psoriasis: results from a population-based study

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

National Psoriasis Foundation clinical consensus on disease severity

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Psoriasis: a possible risk factor for development of coronary artery calcification.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Epidemiology of psoriatic arthritis in the population of the United States.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

CD4+ T-cell–directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2634854

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

4 December 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Prominent Production of IL-20 by CD68+/CD11c+ Myeloid-Derived Cells in Psoriasis: Gene Regulation and Cellular Effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Prevalence of cardiovascular risk factors in patients with psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Update on the epidemiology and systemic treatment of psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Association of patient-reported psoriasis severity with income and employment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Mortality studies in psoriatic arthritis. Results from a single outpatient clinic. I. Causes and risk of death

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

7 January 2021

12 December 2020

Prophylactic digitalis in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Risk of Myocardial Infarction in Patients With Psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Association between psoriasis and the metabolic syndrome. A cross-sectional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Noncutaneous malignant tumors in the PUVA follow-up study: 1975-1996

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Psoriasis, its treatment, and cancer in a cohort of Finnish patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

The Risk of Lymphoma in Patients with Psoriasis

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

7 January 2021

inferred from DOI database lookup

Suicidal ideation in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Psoriasis and psychiatry: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Personality disorders and psychiatric symptoms in psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YADR.2008.09.006

Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention

7 January 2021

1 reference

12 December 2020

The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991

1 reference

12 December 2020

Psoriatic arthritis (PSA)--an analysis of 220 patients

1 reference

12 December 2020

Remittive effects of intramuscular alefacept in psoriasis

1 reference

12 December 2020

Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis

1 reference

12 December 2020

Interleukin 12: Basic Biology and Potential Applications in Cancer Treatment

1 reference

12 December 2020

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Occlusive vascular disease in psoriatic patients

1 reference

12 December 2020

Role of interleukin-17 in cartilage and bone destruction in rheumatoid arthritis

1 reference

12 December 2020

HLA antigens in psoriatic arthritis

1 reference

12 December 2020

10.1016/J.YADR.2008.09.006

Identifiers

DOI

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

19256309

1 reference